PCSK9 and diabetes: Is there a link?

Amir Abbas Momtazi, Maciej Banach, Matteo Pirro, Evan A. Stein, Amirhossein Sahebkar

Research output: Contribution to journalReview article

16 Citations (Scopus)

Abstract

Diabetes mellitus (DM) is associated with an increased risk of cardiovascular disease (CVD). Inhibitors of proprotein convertase subtilisin/kexin type 9 (PCSK9) have emerged as effective low-density lipoprotein cholesterol-lowering compounds. Although the results of available epidemiological, preclinical, and clinical studies suggest a positive association of plasma PCSK9 levels with glycemic parameters and risk of type 2 DM (T2DM), genetic findings have shown contradictory results. Overall, the impact of PCSK9 inhibitors on glycemic control parameters in patients with DM remains unclear. Here, we assess the available evidence for the association of PCSK9 status with the incidence and control of DM in preclinical and clinical studies, and identify molecular mechanisms regulating PCSK9 expression in the diabetic state. Here, we provide a comprehensive overview of preclinical and clinical studies on the role of PCSK9 and PCSK9 inhibition in diabetes.

Original languageEnglish
Pages (from-to)883-895
JournalDrug Discovery Today
Volume22
Issue number6
DOIs
Publication statusPublished - Jun 2017

Fingerprint Dive into the research topics of 'PCSK9 and diabetes: Is there a link?'. Together they form a unique fingerprint.

  • Cite this

    Momtazi, A. A., Banach, M., Pirro, M., Stein, E. A., & Sahebkar, A. (2017). PCSK9 and diabetes: Is there a link? Drug Discovery Today, 22(6), 883-895. https://doi.org/10.1016/j.drudis.2017.01.006